We believe that all the lines with clearly defined genetic backgrounds—i.e., methylation and epigenetic status—the occurrence (or not) of KRAS, BRAF, SMAD4, and other mutations were the best experimental models to identify the particular ABCC4 expression status in CRC to mimic a patient-specific approach. Here, KRAS is linked to colorectal carcinoma.